Never miss another update

Subscribe Today!

Abivax Receives EMA Scientific Advice Supportive of Moving ABX464 into Phase 3 Clinical Testing in Ulcerative Colitis

The responses from the European Medicines Agency (EMA) within the scientific advice meeting support moving 25mg and 50mg ABX464 into a phase 3 clinical program in ulcerative colitis (UC)Abivax to present at the virtual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022, at 12:00-12:40 pm ET (9:00-9:40 am PST and 6:00-6:40 pm CET) PARIS,… Read More »Abivax Receives EMA Scientific Advice Supportive of Moving ABX464 into Phase 3 Clinical Testing in Ulcerative Colitis

The post Abivax Receives EMA Scientific Advice Supportive of Moving ABX464 into Phase 3 Clinical Testing in Ulcerative Colitis appeared on Stocks News Feed.

Posted in

The Markets Today